VLON - Vallon Pharma shares rise 6% on ADAIR update

Vallon Pharmaceuticals (VLON) provides a clinical program update for its lead program, ADAIR, a abuse-deterrent formulation of immediate-release ((IR)) dextroamphetamine currently in development for the treatment of attention deficit hyperactivity disorder ((ADHD)) and narcolepsy. “Our ongoing SEAL study is designed to evaluate the safety and abuse liability of ADAIR by recreational drug users. We are pleased with the progress of the study and remain on track with our expectations to report topline results in the second half of this year, which have the potential to support our NDA filing in the second quarter of 2022,” stated Dr. Timothy Whitaker, Chief Medical Officer. The SEAL study will assess the pharmacodynamics ((PD)), pharmacokinetics, safety and tolerability of manipulated ADAIR 30mg when compared to crushed d-amphetamine sulfate and placebo.The primary PD endpoint is mean maximum (Emax) Drug Liking on a bipolar 100mm visual analog scale, a standard endpoint used in human abuse liability studies.

For further details see:

Vallon Pharma shares rise 6% on ADAIR update